Viswanath Pilla
Journalist at Moneycontrol
Journalist @EconomicTimes. Tracks pharma/healthcare. Previously @moneycontrolcom @livemint @CNBCTV18Live. Views are personal, RTs are not endorsements.
Articles
-
1 week ago |
moneycontrol.com | Viswanath Pilla
India's drug regulator plans to bring in specialists from the private sector and even abroad in its expert review committees to evaluate complex modern therapies, a marked departure from its long-standing reliance on government-only experts. Central Drugs Standard Control Organisation (CDSCO) chief Dr Rajeev Singh Raghuvanshi described the move as a "very important milestone" necessary to keep pace with innovation.
-
1 week ago |
moneycontrol.com | Viswanath Pilla
HomeNewsBusinessCompaniesIndian medical device makers prepare for US push, sensing opportunity from China tariffs Trending TopicsRBI Monetary PolicySensex LiveRepo Rate CutIndia GDP GrowthRBI Monetary Policy Highlights Some of the India medical devices companies have started work on regulatory filings and paperwork, to ensure they do not miss out on the opportunity emerging out of this tariff war.
-
2 weeks ago |
moneycontrol.com | Viswanath Pilla
Such medications are just one part of a necessary, holistic approach that includes diet, exercise, and addressing significant societal stigma, say experts. April 09, 2025 / 18:34 IST The understanding of obesity in India is shifting, with growing recognition that it's a complex disease requiring medical management, not just a lifestyle issue, experts said during a discussion at the News18 Rising Bharat Summit 2025 in Delhi on Wednesday.
-
2 weeks ago |
moneycontrol.com | Viswanath Pilla
Natco Pharma on April 8 said that the launch of its generic version of Roche Pharma's patented drug, Risdiplam, is contingent upon the successful outcome in a patent infringement case. The Hyderabad-based drug maker added that it has decided to price its version of Risdiplam at Rs 15,900. In its exchange filing, the pharma company further added that it intends to offer discount to certain deserving patients through its patient access programme.
-
2 weeks ago |
flipboard.com | Viswanath Pilla
The comprehensive study draws insights from de-identified electronic medical records encompassing over 2.5 million preventive health screenings …
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 1K
- Tweets
- 1K
- DMs Open
- Yes
RT @moneycontrolcom: #Business | Venkat Jasti’s billion-dollar gamble: Can Suven Life crack the CNS drug puzzle? 🏢💊 @viswanath_pilla write…
patient assistance programs (PAPs) offered by MNC pharma cos free of cost will be fully exempted from duties. PAPs of 37 more medicines, 30 new PAPs will get the exemption. @nsitharamanoffc #BudgetwithET
Patients suffering from cancer, rare diseases 36 life saving drugs will be fully exempted from basis custom duty, 6 life saving medicines will have concessional duty of 5%. Even their bulk drugs/API will get exemptions and concessional duty. @nsitharamanoffc #BudgetWithET
